Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / North Dakota

Peptide legality · North Dakota · updated 2026-09-21

Are peptides legal in North Dakota?

Gray area

Peptides sit in a legal gray zone in North Dakota, where FDA-approved medicines such as Wegovy® (semaglutide) are legal with a valid prescription while unapproved research peptides such as BPC-157 have no lawful compounding pathway.

Legal status overview

Peptides sit in a gray zone in North Dakota. The state has no peptide-specific statute, so access is governed by the federal Food, Drug, and Cosmetic Act, FDA compounding rules under sections 503A and 503B, and the licensing authority of the North Dakota State Board of Pharmacy. FDA-approved GLP-1 receptor agonist medicines such as Ozempic® (semaglutide) and Zepbound® (tirzepatide) are legal when prescribed by a licensed clinician, while unapproved research peptides such as BPC-157 and TB-500 cannot be lawfully compounded or sold for human use. Compounded medications are not FDA-approved, are not a generic, and have not been evaluated by the FDA.

Key points

  • North Dakota has no peptide-specific law; peptide access follows the federal FDA framework layered over North Dakota State Board of Pharmacy licensing of pharmacies and pharmacists. [1]
  • North Dakota compounding pharmacies operate under FDA section 503A, which limits compounding to bulk substances that meet a USP or NF monograph, are components of FDA-approved drugs, or appear on the FDA 503A bulks list. [3]
  • BPC-157 remains in Category 2 of the FDA interim 503A bulks list, so licensed 503A compounding pharmacies may not compound it for any patient or indication. [5]
  • FDA-approved GLP-1 receptor agonist medicines are legal by prescription in North Dakota, where MD, DO, NP, APRN, and PA clinicians may prescribe them. [7]
  • After the FDA declared the GLP-1 shortage resolved, compounding drug products that are essentially copies of approved GLP-1 medicines is generally not permitted absent a documented patient-specific clinical need. [4]
  • Growth hormone (somatropin) is an FDA-approved prescription drug, and federal law makes distributing it for non-approved uses such as anti-aging or bodybuilding a criminal offense. [6]
  • Research-use-only peptides sold outside the regulated pharmacy channel are not lawful for human use and may not be used in compounding. [5]
  • Compounded medications, including compounded semaglutide, are not FDA-approved, are not a generic, and have not been evaluated by the FDA. [4]

Compound-by-compound status

BPC-157
Restricted
Unapproved drug with no USP or NF monograph; sits in Category 2 of the FDA interim 503A bulks list, so it cannot be lawfully compounded or sold for human use in North Dakota.
GLP-1 receptor agonist class (Wegovy® (semaglutide), Ozempic® (semaglutide), Zepbound® (tirzepatide), Mounjaro® (tirzepatide))
Legal
FDA-approved brands are legal by prescription; compounded versions are restricted after the shortage resolution and are not FDA-approved, not a generic, and not evaluated by the FDA.
TB-500 (thymosin beta-4)
Restricted
Unapproved drug that does not appear on the FDA 503A bulks list; not lawful to compound or to sell for human use in North Dakota.
Growth hormone / somatropin
Restricted
FDA-approved prescription drug limited to specific medical indications; federal law criminalizes distribution for non-approved uses such as anti-aging, athletic performance, or bodybuilding.

Frequently asked questions

Are peptides legal in North Dakota?

It depends on the peptide. FDA-approved medicines such as Wegovy® (semaglutide) are legal with a valid prescription, while unapproved research peptides such as BPC-157 and TB-500 have no lawful pathway for human use. This is information, not medical or legal advice.

Can a North Dakota pharmacy compound BPC-157?

No. BPC-157 is an unapproved drug in Category 2 of the FDA interim 503A bulks list, so licensed North Dakota compounding pharmacies may not compound it.

Is compounded semaglutide the same as Wegovy® or Ozempic®?

No. Compounded semaglutide is not FDA-approved, is not a generic, and has not been evaluated by the FDA, unlike the approved brands Wegovy® (semaglutide) and Ozempic® (semaglutide).

Who can prescribe GLP-1 medicines in North Dakota?

Licensed MD, DO, NP, APRN, and PA clinicians may prescribe FDA-approved GLP-1 receptor agonist medicines in North Dakota.

Is growth hormone legal in North Dakota?

Somatropin is an FDA-approved prescription drug for specific medical conditions. Federal law makes distributing it for non-approved uses such as anti-aging or bodybuilding a crime.

General information based on the sourced research above, not legal advice. For a specific situation in North Dakota, consult a licensed attorney familiar with pharmaceutical law.